Expertise in

conditions

Ingrid E. Scheffer

50 Flemington Rd,

Parkville, VIC, AU

Expertise in

conditions

50 Flemington Rd,

Parkville, VIC, AU

Overview

Ingrid Scheffer practices practicing medicine in Parkville, Australia.

Ms. Scheffer is highly rated in 62 conditions, according to our data. Her clinical expertise encompasses Myoclonic Epilepsy, West Syndrome, Epilepsy, and Epilepsy with Myoclonic-Atonic Seizures.

She is actively involved in clinical research, co-authoring 526 peer reviewed articles and participating in 4 clinical trials.

Gender

Female

Locations

50 Flemington Rd, Parkville, VIC 3052, Australia

Other Locations

Flemington Road, Melbourne, VIC, Australia

245 Burgundy St, Heidelberg, VIC 3084, Australia

Burgundy Street, Melbourne, VIC 3084, Australia

Banksia Street, Heidelberg, VIC 3081, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS)

Enrollment Status: Completed

Publish Date: September 04, 2026

Intervention Type: Drug

Study Drug: Soticlestat

Study Phase: Phase 3

A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)

Enrollment Status: Terminated

Publish Date: September 04, 2026

Intervention Type: Drug

Study Drug: Soticlestat

Study Phase: Phase 3

Enrollment Status: Completed

Publish Date: August 21, 2024

Intervention Type: Drug

Study Drug: Soticlestat

Study Phase: Phase 3

ANAVEX2-73-RS-003 is a Phase 2/3, Double-blind, Randomized, Placebo-controlled Safety and Efficacy Study in Pediatric Patients With RTT

Enrollment Status: Completed

Publish Date: August 21, 2023

Intervention Type: Drug

Study Drug: ANAVEX2-73

Study Phase: Phase 2/Phase 3

View 3 Less Clinical Trials

521 Total Publications

Efficacy and safety of fenfluramine in Dravet syndrome: The impact of patient clinical characteristics.

Journal: Epilepsia open

Published: June 08, 2026

View All 521 Publications

Frequently Asked Questions about Ingrid E. Scheffer

Is Ingrid E. Scheffer a top-rated expert for Myoclonic Epilepsy?

MediFind is an objective health platform that identifies experts based on real-world data. Ingrid E. Scheffer is classified as an Elite expert for Myoclonic Epilepsy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ingrid E. Scheffer participate in research or clinical trials?

Yes. Ingrid E. Scheffer has published 521 articles and abstracts on conditions like Myoclonic Epilepsy. You can view a list of Ingrid E. Scheffer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Scheffer's expertise for a condition

ConditionClose